Wells Fargo & Company Infinity Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	SELL	$0.14 - $0.24 $838 - $1,437	-5,990 Reduced 20.14%	23,750 $4,000
Q1 2023 May 12, 2023	SELL	$0.16 - $0.74 $13,675 - $63,247	-85,470 Reduced 74.19%	29,740 $4,000
Q4 2022 Feb 13, 2023	SELL	$0.46 - $1.21 $108,436 - $285,234	-235,731 Reduced 67.17%	115,210 $64,000
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.7 $62,453 - $179,951	-105,854 Reduced 23.17%	350,941 $418,000
Q2 2022 Aug 12, 2022	SELL	$0.49 - $1.2 $219,712 - $538,070	-448,392 Reduced 49.54%	456,795 $289,000
Q1 2022 May 16, 2022	SELL	$0.85 - $2.4 $222,947 - $629,498	-262,291 Reduced 22.47%	905,187 $1.03 Million
Q4 2021 Feb 14, 2022	SELL	$1.86 - $3.36 $925,839 - $1.67 Million	-497,763 Reduced 29.89%	1,167,478 $2.63 Million
Q3 2021 Nov 15, 2021	BUY	$1.52 - $3.82 $2.52 Million - $6.33 Million	1,656,811 Added 19653.75%	1,665,241 $5.7 Million
Q2 2021 Aug 16, 2021	SELL	$2.66 - $3.47 $1,468 - $1,915	-552 Reduced 6.15%	8,430 $25,000
Q1 2021 May 13, 2021	BUY	$1.98 - $5.36 $265 - $718	134 Added 1.51%	8,982 $29,000
Q4 2020 Feb 09, 2021	BUY	$1.05 - $2.77 $59 - $157	57 Added 0.65%	8,848 $19,000
Q3 2020 Nov 05, 2020	SELL	$0.82 - $1.34 $18 - $30	-23 Reduced 0.26%	8,791 $10,000
Q2 2020 Aug 13, 2020	SELL	$0.77 - $1.13 $668 - $980	-868 Reduced 8.97%	8,814 $8,000
Q1 2020 May 14, 2020	BUY	$0.69 - $1.52 $6,680 - $14,716	9,682 New	9,682 $8,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.